Mabwell's MAIWEIJIAN Denosumab Injection Receives NMPA Acceptance for Expanded Cancer Bone Complications Treatment

Key Takeaways

• China’s NMPA has accepted Mabwell’s supplemental biologics license application for MAIWEIJIAN (denosumab injection) to expand treatment indications
• The expanded approval targets prevention of skeletal-related events in multiple myeloma patients and those with bone metastases from solid tumors
• This regulatory milestone positions Mabwell’s T-mab subsidiary to compete in China’s growing oncology supportive care market

---

NMPA Accepts Expanded Indication for Mabwell’s Denosumab

Shanghai-based Mabwell (688062.SH) announced April 16, 2026, that China’s National Medical Products Administration (NMPA) has accepted a supplemental Biologics License Application for MAIWEIJIAN (denosumab injection), expanding its use to prevent skeletal-related events in cancer patients.

The application, submitted by Mabwell’s wholly-owned subsidiary T-mab, seeks approval for MAIWEIJIAN (R&D code: 9MW0321) to treat patients with multiple myeloma and those experiencing bone metastases from solid tumors.

Market Impact and Clinical Significance

This regulatory acceptance represents a significant expansion opportunity for Mabwell in China’s oncology market. Denosumab, a monoclonal antibody targeting RANKL, has proven effective in reducing bone complications that frequently plague cancer patients, including fractures, spinal cord compression, and the need for radiation or surgery to bone.

Multiple myeloma affects approximately 176,000 new patients globally each year, with bone disease occurring in up to 90% of cases. Similarly, bone metastases develop in 65-80% of patients with advanced breast and prostate cancers, creating substantial unmet medical needs.

Competitive Landscape

MAIWEIJIAN enters a market currently dominated by Amgen’s original denosumab (Xgeva/Prolia) and other bisphosphonate therapies. As a biosimilar, MAIWEIJIAN could offer cost advantages while maintaining therapeutic efficacy, potentially improving patient access to this critical supportive care treatment.

Regulatory Timeline

While NMPA acceptance doesn’t guarantee approval, it indicates the application meets regulatory standards for review. The typical NMPA review process for supplemental biologics applications ranges from 12-18 months, suggesting potential market entry by late 2027.

Mabwell’s integrated biopharmaceutical platform, spanning research through commercial manufacturing, positions the company to rapidly scale production upon approval. This vertical integration strategy has become increasingly valuable as China emphasizes domestic biopharmaceutical capabilities.

---

Frequently Asked Questions

What does this NMPA acceptance mean for cancer patients in China?

NMPA acceptance means Mabwell’s MAIWEIJIAN denosumab is under regulatory review for expanded use in preventing bone complications in multiple myeloma and solid tumor patients, potentially providing a more affordable treatment option.

When will MAIWEIJIAN be available for these new indications?

Following typical NMPA review timelines of 12-18 months, MAIWEIJIAN could potentially receive expanded approval by late 2027, though this depends on successful completion of the regulatory review process.

How does MAIWEIJIAN compare to existing denosumab treatments?

As a biosimilar to Amgen’s denosumab, MAIWEIJIAN is designed to provide equivalent therapeutic benefits while potentially offering cost advantages and improved access for Chinese patients with cancer-related bone complications.